Unicycive Therapeutics Inc (UNCY)

$UNCY All actually marketed phosphate binders got a TDAPA designation, starting with 1.1.2025. When UNCY's OLC is launched, 1.1.2027 potentially, the designation will also be granted, however the designation for all other oral phosphate binders may end. Thus, OLC will be the drug of choice for all dialysis centers and grab immediately a majority market share.

$UNCY WestPark Capital initiated coverage with a BUY at $72!

$UNCY @SlapThatAsssk hey by chance have you r e searched this? Any thoughts?

$UNCY started a position with 300 shares!! Resubmitted the FDA application for minor manufacturing corrections! The ride to $90 will be fun 🚀

$UNCY Unicycive Therapeutics; early-stage renal biotech; binary catalysts.

$UNCY Weenie measuring contest time. I’ve got 14k shares. This hits about $70 a share it’ll be a million bucks. Anyone else?

$UNCY Nantahala Capital Management had 939.2k 4.37% Nov 14, 2025 Now they are reporting 2,281.040 shares ...9.99% https://ir.stockpr.com/unicycive/sec-filings-email/content/0001104659-26-015349/primary_doc.html

$UNCY According to Simoly Ws: Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$30M free cash flow). Shareholders have been substantially diluted in the past year (107% increase in shares outstanding). Revenue is less than US$1M. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). I am loading more when dropped beliw $6 anyway 🟢🟢🟢

$UNCY mega bullish!

$UNCY Just a thought, I don’t think we will go much up on approval looking at how marker behaves recently. NVCR got fda approval for a Cancer treatment, rare pancreatic cancer, and price popped 50% up AH just to drop 20% on open next day. If such news only take it 30% up, I will be setting up my sell at $8.50 max here ... if we get to that on approval.

$UNCY was fire chat any good ?

$UNCY Just finished listening to Gupta at the Guggenhiem bio conference. He sounded pretty confident that the FDA would approve. Also talked about being ready to roll product out for 3rd quarter this year and applying for TDAPA as soon as they are approved. He said the application for TDAPA is done electronically and they have everything ready to submit just waiting on FDA approval.

$UNCY This presentation allowed no questions. What are they hiding?

$UNCY what’s your thought ? Buy more now? Wait? I have a lot of this

$UNCY Current Stock Price: $6.47 Contracts to trade: $7.5 UNCY Feb 20 2026 Call Entry: $0.14 Exit: $0.24 ROI: 74% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

$UNCY is a clinical-stage biotech focused on oncology; its valuation is entirely event-driven by preclinical and early clinical data readouts.

$UNCY https://www.sec.gov/Archives/edgar/data/1766140/000110465926006264/xslSCHEDULE_13G_X01/primary_doc.xml Integrated Core Strategies (us) Llc ownership in UNCY / Unicycive Therapeutics, Inc. 2026-01-23 - Integrated Core Strategies (us) Llc has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,172,667 shares of Unicycive Therapeutics, Inc. (US:UNCY). This represents 5.5 percent ownership of the company.

Unicycive Therapeutics (Nasdaq: $UNCY) announced that Dr. Shalabh Gupta, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 1:30 p.m. ET. Unicycive Therapeutics (Nasdaq: $UNCY) is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/unicycive. A link to the live and archived webcast is available on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1x1 meeting with management, please contact your Guggenheim conference representative. See the press release at https://ir.unicycive.com/news/detail/119/unicycive-therapeutics-to-participate-in-a-fireside-chat-at. Unicycive Therapeutics is a clinical-stage biotechnology company developing innovative therapies for kidney diseases. The company’s lead investigational treatment, oxylanthanum carbonate, is a novel phosphate-binding agent for treating hyperphosphatemia in patients with chronic kidney disease who are on dialysis and is currently under review by the U.S. Food and Drug Administration. Its second program, UNI-494, targets conditions related to acute kidney injury and has received FDA orphan drug designation for preventing delayed graft function in kidney transplant patients. Led by CEO Dr. Shalabh Gupta and a seasoned executive team including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, and Dr. Guru Reddy, Unicycive is committed to addressing unmet needs in kidney disease treatment. Learn more at Unicycive (https://unicycive.com/) and B2i Digital (https://b2idigital.com/). Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted UNCY stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of UNCY or any security, and it is not intended to offer any opinion on UNCY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. ​$XBI

$UNCY Scheduled to present at the Guggenheim Emerging Outlook Biotech Summit. February 11, 2026 1:30 pm EST Registration link https://event.summitcast.com/view/kbtj9ZAiVkB78KPZiu5dZ9/AZSxGz222inPHqZ5CLzskA

$UNCY This article is riddled with misinformation and outright errors. The most glaring mistake is about Xphozah. Xphozah is NOT a phosphate binder. Nanoparticle technology is completely made up.

$UNCY Excellent article that nails exactly where UNCY stands right now. So if you want to update your UNCY knowledge or get acquainted with UNCY, this is a must read. https://everyticker.com/quote/UNCY/analysis/unicycive-therapeutics-awaiting-the-oxylanthanum-carbonate-verdict-amidst-financial-pressures-nasdaq-uncy

$UNCY institutional investirs are loading slowly 💪💪🏋️‍♂️